Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SCIP subcutaneous benzathine penicillin G for rheumatic fever and rheumatic heart disease
ACTRN12625000031460Phase 2Recruiting
- Sponsor
- The Kids Research Institute Australia
- Start
- Oct 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of benzylpenicillin in rheumatic fever (RF) and rheumatic heart disease (RHD), sponsored by The Kids Research Institute Australia. Primary endpoints: Acceptability of SCIP implementation, Self-reported tolerability of SCIP administration and 1 more. Started Oct 2025; status: recruiting.
02
Drugs
benzylpenicillin
03
Conditions
rheumatic fever (RF)rheumatic heart disease (RHD)
Beyond the preview
Go deeper on ACTRN12625000031460.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ACTRN12625000031460.